Related Experiment Videos

Purplish, pruritic papules on the limbs

J C Cather¹, M A Menter

¹Division of Dermatology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.

Proceedings (Baylor University. Medical Center)

|December 22, 2005

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.

The British journal of dermatology·2021

Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.

The British journal of dermatology·2018

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

The British journal of dermatology·2016

See all related articles